AbbVie Inc. (ABBV) Thursday announced that Ontario and Quebec, under new early access process, will reimburse subcutaneous Epkinly, for the treatment of diffuse large B cell Lymphoma.
Epkinly, an IgG1-bispecific antibody, is now listed on the Ontario Health for the treatment of adult patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy.
Diffuse large B cell Lymphoma or DLBCL is a type of aggressive, fast-growing non-Hodgkin's lymphoma and is the most common type of NHL.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.